ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Benzinga11-11

On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy adrenaline (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482408785?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8k6dOAMEvDt7_PBLdOtQ9w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/389ac3d6254a811ad876f37cecec65bf","is_english":true,"pubTime":"2024-11-11 20:41","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482408785","market":"us","top_or_hot":-1,"title":"ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024","media":"Benzinga","content":"<div>\n<p>On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY).\nThe agreement grants ALK exclusive global rights to the neffy adrenaline (...</p>\n\n<a href=\"https://finance.yahoo.com/news/ars-pharmaceuticals-inks-licensing-pact-124139720.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ars-pharmaceuticals-inks-licensing-pact-124139720.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY).\nThe agreement grants ALK exclusive global rights to the neffy adrenaline (...</p>\n\n<a href=\"https://finance.yahoo.com/news/ars-pharmaceuticals-inks-licensing-pact-124139720.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inks-licensing-pact-124139720.html","article_id":"2482408785","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8k6dOAMEvDt7_PBLdOtQ9w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/389ac3d6254a811ad876f37cecec65bf"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482408785","pubTimestamp":1731328899,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. .The agreement grants ALK exclusive global rights to theneffy adrenaline  nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.In August, the FDA approvedARS Pharmaceuticals’ Neffy  for the emergency treatment of allergic reactions , including those that are life-threatening , foradult and pediatric patients.Neffy is also approved in Europe. Submission for regulatory approval in Canada is planned for by the end of 2024.ARS Pharma is also developing its intranasal adrenaline  technology for acute flares in patients with chronic urticaria, with plans to begin a Phase 2b trial in 2025.The license agreement gives ALK exclusive rights for new indications in the licensed territories.ALK will initially focus on bringingNeffy to Europe and Canada, the world’s second and third-largest adrenaline autoinjector markets. In both markets, the product can be added to ALK’s exi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRY":"ARS PHARMACEUTICALS INC"},"translate_title":"ARS Pharmaceuticals签署Neffy过敏反应治疗许可协议，分析师认为尽管2024年股价将飙升200%，但股价仍将进一步上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY).\nThe agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.\nIn August, the FDA approved ARS Pharmaceuticals’ Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients.\nNeffy is also approved in Europe. Submission for regulatory approval in Canada is planned for by the end of 2024.\nARS Pharma is also developing its intranasal adrenaline (epinephrine) technology for acute flares in patients with chronic urticaria, with plans to begin a Phase 2b trial in 2025.\nThe license agreement gives ALK exclusive rights for new indications in the licensed territories.\nALK will initially focus on bringing Neffy to Europe and Canada, the world’s second and third-largest adrenaline autoinjector markets. In both markets, the product can be added to ALK’s existing infrastructure and sales channels.\nThe agreement also holds potential in other markets, e.g., Asia and the Middle East.\nALK estimates that Neffy holds a long-term annual peak sales potential in anaphylaxis of up to 3 billion Danish Kroner (around $430 million) in the licensed territories.\nThere may be substantial upsides to this potential from new indications, e.g., urticaria.\nUnder the agreement, ARS Pharma is entitled to receive an upfront payment of $145 million (1 billion Danish kroner) from ALK.\nFurthermore, ARS Pharma may receive up to $320 million (2.2 billion Danish Kroner) related to regulatory and commercial milestones, potentially over the next 15+ years as well as tiered royalties in the teens on future sales.\nARS Pharma will supply finished goods to ALK, while ALK will be responsible for local market access, marketing and sales.\nThe first launches are expected to take place in Europe in 2025 once local market access negotiations are completed.\nWilliam Blair highlights that ARS Pharmaceuticals’ stock has jumped more than 200% this year but believes there is still room for more growth. The firm points to a strong launch of Neffy, which could surpass current market expectations as the main driver.\nThe analyst notes that survey results indicate significant demand for neffy in the near future. Early-stage payer coverage has been better than expected, supporting a solid launch through 2025. With Neffy standing out as an approved, unique product, the analyst expects a strong commercial rollout and blockbuster-level peak sales.\nWilliam Blair maintains the Outperform rating for ARS Pharmaceuticals stock.\nPrice Action: SPRY stock is up 4.99% at $17.89 during the premarket session at last check Monday.\nPhoto via Shutterstock\nRead Next:\n\nBristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482408785"}